396 related articles for article (PubMed ID: 10161371)
21. Filgrastim in patients with neutropenia: potential effects on quality of life.
Lyman GH; Kuderer NM
Drugs; 2002; 62 Suppl 1():65-78. PubMed ID: 12479595
[TBL] [Abstract][Full Text] [Related]
22. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
[TBL] [Abstract][Full Text] [Related]
23. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
Numnum TM; Kimball KJ; Rocconi RP; Kilgore LC; Straughn JM
Int J Gynecol Cancer; 2007; 17(5):1019-24. PubMed ID: 17386043
[TBL] [Abstract][Full Text] [Related]
24. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
25. A predictive model for neutropenia associated with cancer chemotherapy.
Lyman GH
Pharmacotherapy; 2000 Jul; 20(7 Pt 2):104S-111S. PubMed ID: 10905685
[TBL] [Abstract][Full Text] [Related]
26. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
27. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
28. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
29. Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.
Frasci G
Drugs; 2002; 62 Suppl 1():17-31. PubMed ID: 12479592
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
Frampton JE; Keating GM
BioDrugs; 2005; 19(6):405-7. PubMed ID: 16392893
[TBL] [Abstract][Full Text] [Related]
31. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
32. Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.
Ratti M; Tomasello G
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):15-24. PubMed ID: 25409861
[TBL] [Abstract][Full Text] [Related]
33. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
Biganzoli L; Untch M; Skacel T; Pico JL
Semin Oncol; 2004 Jun; 31(3 Suppl 8):27-34. PubMed ID: 15181606
[TBL] [Abstract][Full Text] [Related]
34. Cost considerations in therapy with myeloid growth factors.
Glaspy JA; Jakway J
Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
[TBL] [Abstract][Full Text] [Related]
35. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
Glaspy JA; Bleecker G; Crawford J; Stoller R; Strauss M
Eur J Cancer; 1993; 29A Suppl 7():S23-30. PubMed ID: 7508727
[TBL] [Abstract][Full Text] [Related]
36. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
[TBL] [Abstract][Full Text] [Related]
37. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.
Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353
[TBL] [Abstract][Full Text] [Related]
38. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation.
Messori A; Trippoli S; Tendi E
J Clin Pharm Ther; 1996 Apr; 21(2):57-63. PubMed ID: 8809640
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.
Fust K; Li X; Maschio M; Barron R; Weinstein MC; Parthan A; Walli-Attaei M; Chandler DB; Lyman GH
Gynecol Oncol; 2014 Jun; 133(3):446-53. PubMed ID: 24657302
[TBL] [Abstract][Full Text] [Related]
40. Future strategy for cancer treatment using recombinant human granulocyte colony stimulating factor.
Diehl V
Eur J Cancer; 1994; 30A Suppl 3():S44-7. PubMed ID: 7535072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
